Myriad Marketing Mix
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
GET THE FULL COMPANY
ANALYSIS BUNDLE FOR
Myriad
Built for Strategy. Ready in Minutes.
Discover how Myriad’s product design, pricing tiers, distribution channels, and promotion mix combine to create market impact—this preview highlights key strengths and gaps, but the full 4Ps Marketing Mix Analysis delivers an editable, data-backed report with actionable strategies, benchmarks, and ready-to-use slides to fast-track your planning and presentations.
Product
MyRisk Hereditary Cancer Test
MyRisk Hereditary Cancer Test uses a 35-gene panel to detect mutations linked to eight primary hereditary cancers, informing surgical and surveillance choices with >95% analytic sensitivity for pathogenic variants.
By end-2025 MyRisk added integrated polygenic risk scores (PRS) calibrated across European, African, and Asian ancestries, improving risk stratification: PRS raised net reclassification by ~12% in validation cohorts (n≈42,000).
The test generated ≈$110M revenue in 2024 for Myriad Genetics (Myriad Genetics, Inc., ticker MYGN) and remains a market leader by combining single-gene, multi-gene, and PRS data into actionable clinical reports used in >1,200 US clinics.
GeneSight Psychotropic Pharmacogenomics
GeneSight Psychotropic Pharmacogenomics analyzes patient DNA to predict response to antidepressants and antipsychotics, cutting trial-and-error prescribing; Myriad reported GeneSight revenue of $168M in FY2024, up ~14% year-over-year.
The test uses a color-coded system (green/yellow/red) to flag likely tolerability and efficacy, guiding clinicians in primary care and psychiatry where studies show genotype-guided prescribing can reduce treatment failure by ~30%.
Precise Oncology Solutions
Myriad’s Precise Oncology Solutions bundle tumor profiling, liquid biopsy, and germline tests to guide precision cancer care; by 2025 the suite includes MRD (minimal residual disease) monitoring via blood draws, improving early recurrence detection with reported sensitivity ~0.01% variant allele fraction and reducing relapse lead-time by months in published cohorts.
Prequel and Foresight Women's Health
Prequel NIPT and Foresight carrier screening are Myriad Genetics' flagship women's health products, driving a segment that delivered about $370M in 2025 revenue for hereditary and women's health combined; Prequel uses high-depth sequencing to detect common aneuploidies with >99% sensitivity and maintains performance in high-BMI patients.
Foresight tests prospective parents for >175 inherited conditions, informing reproductive decisions; combined test uptake supported a ~12% year-over-year volume growth in 2025.
- Prequel: >99% sensitivity for trisomies
- Performs well at BMI >35
- Foresight: >175 conditions screened
- 2025 segment revenue ~ $370M
- Volume growth ~12% YoY (2025)
Myriad ME Digital Insights Platform
The Myriad ME Digital Insights Platform integrates genetic test results with longitudinal health records and clinical updates, enabling ongoing patient monitoring; Myriad reported a 23% increase in recurring service revenue in 2024 from platform subscriptions.
It converts complex genomic data into concise, actionable reports for clinicians and patients, reducing time-to-action by an estimated 40% in pilot studies and improving guideline-aligned interventions by 18%.
This software-driven model shifts Myriad from single-test sales to continuous engagement, boosting lifetime customer value and supporting a subscription-driven strategy with reported 30% gross margins on platform services.
- Integrates genomics + longitudinal EHR data
- 23% recurring revenue growth in 2024
- 40% faster clinician action in pilots
- 18% more guideline-aligned interventions
- 30% gross margin on subscription services
Myriad: High‑precision genetic tests—MyRisk, GeneSight, Prequel/Foresight, Precise Oncology
Myriad’s product mix centers on MyRisk (35-gene hereditary cancer + PRS; >95% analytic sensitivity; PRS net reclassification +12%, n≈42,000), GeneSight (pharmacogenomics; $168M FY2024; reduces treatment failure ~30%), Precise Oncology (tumor/germline/MRD; MRD sensitivity ~0.01% VAF), Prequel/Foresight (women’s health; >99% trisomy sensitivity; Foresight >175 conditions; 2025 segment rev ~$370M).
| Product | Key metric | 2024/2025 $ |
|---|---|---|
| MyRisk | 35 genes; PRS +12% reclass | — |
| GeneSight | Pharmaco; ↓failure ~30% | $168M (FY2024) |
| Prequel/Foresight | >99% trisomy; >175 cond | $370M (2025 seg) |
| Precise Oncology | MRD sens ~0.01% VAF | — |
What is included in the product
Detailed Word Document
Delivers a concise, company-specific deep dive into Myriad’s Product, Price, Place, and Promotion strategies—grounded in actual brand practices and competitive context—to help managers, consultants, and marketers benchmark positioning, repurpose insights for reports or presentations, and adapt the Word file for workshops, market-entry plans, or strategy audits.
Customizable Excel Spreadsheet
Condenses Myriad’s 4P analysis into a concise, at-a-glance summary that speeds decision-making and aligns leadership quickly.
Place
Centralized High-Complexity Laboratories
Myriad performs most testing in centralized, CLIA-certified and CAP-accredited labs in Salt Lake City, processing over 1.2 million tests in 2024 to ensure strict quality control and reproducibility. This hub model delivered a 22% reduction in per-sample sequencing costs versus decentralized peers in 2024, driving gross margin stability. In-house processing guarantees standardized accuracy and a single global reporting pipeline, cutting average turnaround time to 7 days. Centralization supports scalable R&D integration and regulatory compliance worldwide.
Direct Physician Sales Force
Myriad deploys a specialized direct sales force of ~600 reps (2025), targeting high-volume oncologists, psychiatrists, and OB/GYNs to drive clinical adoption of genetic tests.
Reps train clinicians to integrate tests into workflows and help with insurance authorization; direct placement boosts test-order rates by an estimated 15–25% per targeted practice.
Strategic Health System Integrations
Myriad pursues partnerships with major hospital systems and academic medical centers to be the preferred diagnostic provider, securing contracts that can drive millions in annual revenue—examples include deals projected to add $20–40M in testing volume annually as of 2025.
Agreements embed Myriad’s ordering and reporting tools into institutional EHRs (Epic, Cerner), cutting order time and errors and increasing clinician adoption by up to 30% in pilot studies.
Deep EHR integration lowers admin friction, locks in high-volume pipelines, and stabilizes cash flow: integrated accounts can represent 25–40% of system lab volume over three years.
International Licensing and Distribution
Myriad expands globally via direct sales in priority markets and distribution partners across Europe and Japan, cutting time-to-market and scale costs; partners handled regulatory submissions and reimbursement negotiations that in 2024 reduced approval timelines by ~30% versus new-market solo entries.
This approach lets Myriad scale oncology and pharmacogenomic tests without building local labs, keeping capital expenditure lower—estimated savings of $40–60M per major region based on 2023 market-entry cost benchmarks.
- Direct sales in key regions + partners in Europe/Japan
- Partners manage regs and reimbursement, ~30% faster approvals (2024)
- Capex avoidance ~$40–60M per region (2023 benchmarks)
Digital Patient and Provider Portals
Myriad’s digital patient and provider portals act as a virtual distribution channel, letting providers order tests and patients access results securely online, supporting 24/7 access and HIPAA-compliant data flow.
Portals enable telehealth genetic counseling—Myriad reported a 35% rise in virtual consults in 2024—and extend services to rural patients who lack local specialty care.
The digital-first model boosts convenience and reach; in 2024 Myriad cited a 22% increase in test volume through online orders and reduced turnaround times by 12%.
- Virtual channel: online orders + secure results
- Telehealth: 35% rise in virtual consults (2024)
- Access: 22% more tests via portals (2024)
- Efficiency: 12% faster turnaround (2024)
Salt Lake CLIA Lab: 1.2M Tests, 22% Cost Cut, 7‑Day TAT, Digital & Reps Fuel Growth
Centralized CLIA/CAP lab in Salt Lake City processed 1.2M tests (2024), cutting per-sample sequencing costs 22% and TAT to 7 days; ~600 direct reps (2025) boost orders 15–25%; EHR embeds raise adoption up to 30%; portals drove 22% more online orders and 35% rise in telehealth consults (2024).
| Metric | 2024/25 |
|---|---|
| Tests processed | 1.2M |
| Cost reduction | 22% |
| TAT | 7 days |
| Sales reps | ~600 |
| Online order lift | 22% |
What You See Is What You Get
Myriad 4P's Marketing Mix Analysis
The preview shown here is the actual Myriad 4P's Marketing Mix Analysis you’ll receive instantly after purchase—fully complete, editable, and ready for immediate use with no surprises.
Promotion
Peer-Reviewed Clinical Publications
Myriad prioritizes publishing rigorous clinical utility studies in top-tier journals to prove test validity and drive adoption; peer-reviewed evidence helped Myriad report a 12% lift in payer coverage decisions and supported $250M in reimbursed revenue in 2024. These publications persuade clinicians and payers by linking test results to patient outcomes and cost savings, building scientific leadership in molecular diagnostics and reducing reimbursement denials by 18% year-over-year.
Medical Science Liaison Engagement
Myriad employs ~50 Medical Science Liaisons (MSLs) who run peer-to-peer scientific exchanges with key opinion leaders and academic researchers, driving clinical adoption in oncology and hereditary risk testing.
MSLs deliver deep technical education on genomic medicine—covering assay sensitivity, variant interpretation, and new evidence—rather than sales pitches; in 2024 these engagements supported a 12% increase in referral volume for complex cases.
This scientific outreach helps shape clinical guidelines and payer coverage decisions; internal tracking showed MSL-influenced trials and consensus statements contributed to a 9% rise in guideline-cited Myriad tests in 2023–2024.
Direct-to-Consumer Awareness Campaigns
Myriad spends heavily on targeted digital and social campaigns to educate patients on genetic testing for cancer risk and mental health, using patient stories and explainer content to prompt doctor conversations about tests like GeneSight; in 2024 Myriad reported direct-to-consumer ad spend rising ~18% year-over-year to roughly $28M.
Professional Medical Congresses
Myriad keeps a dominant presence at ASCO and APA, using those stages to unveil clinical data, launch product updates, and network with global healthcare decision-makers; in 2024 Myriad presented at 12 major congress sessions and cited a 15% uplift in clinician inquiries post-congress.
These congresses keep Myriad top-of-mind for clinicians—the primary gatekeepers for genetic testing—supporting steady test volume growth (≈+6% YoY in 2024) and contributing to recurring revenue.
- 12 sessions presented in 2024
- 15% increase in clinician inquiries post-congress
- ≈6% YoY test volume growth in 2024
Patient Advocacy Partnerships
Myriad partners with non-profits and patient advocacy groups to expand genetic screening access and health equity, targeting underserved communities; in 2024 these programs reached ~45,000 people through 120 outreach events and subsidized tests covering an estimated $3.2M in waived fees.
These collaborations deliver education for high-risk hereditary conditions, align with partner missions, and boost Myriad’s brand equity while aiming to reduce late-stage diagnoses and long-term care costs.
- 45,000 people reached (2024)
- 120 outreach events (2024)
- $3.2M in subsidized testing (2024)
Myriad drives $250M reimbursed revenue with +6% test growth via MSLs, DTC & partnerships
Myriad uses peer-reviewed studies, 50 MSLs, targeted DTC ads, congress presence, and NGO partnerships to drive clinician adoption, payer coverage, and patient awareness—yielding +6% test volume, $250M reimbursed revenue, 12% lift in coverage decisions, $28M DTC spend, 45,000 outreach reach (2024).
| Metric | 2024 |
|---|---|
| Reimbursed revenue | $250M |
| Test volume YoY | +6% |
| DTC spend | $28M |
| MSLs | 50 |
| Outreach reach | 45,000 |
Price
Managed Care and Insurance Reimbursement
Myriad prices tests mainly via negotiated reimbursement from private insurers, Medicare, and Medicaid; in 2024 reimbursement accounted for ~78% of revenues, per company filings.
The firm spends heavily on market-access teams—Myriad reported $82M in 2024 selling, general & admin tied to payer engagement—to secure coverage that keeps most patients’ out-of-pocket near zero.
This payer-centric pricing sustains high test volumes: Myriad processed ~410k tests in 2024, making costly genomic assays broadly accessible.
Transparent Out-of-Pocket Estimations
Myriad offers automated, transparent out-of-pocket estimates before testing, cutting patient cost uncertainty; in 2024 this feature correlated with a 22% drop in cancellations and a 14-point rise in patient satisfaction scores versus peers. By showing expected copays and insurer coverage up front, Myriad reduces financial anxiety tied to molecular diagnostics and shortens decision time to test. Trust with clinicians grows as billing surprises fall and adherence improves.
Financial Assistance and Access Programs
Myriad offers sliding-scale fees and payment plans for uninsured or underinsured patients meeting income thresholds, lowering out-of-pocket costs; in 2024 the company reported financial assistance to over 45,000 patients, covering an estimated $18 million in billed services.
Tiered Enterprise Pricing Models
Myriad offers tiered enterprise pricing for large health systems, cutting per-test rates by 15–30% for volume commitments above 5,000 samples/year and deeper discounts for multi-year contracts (typical 3–5 years) to lock predictable revenue.
This model ties integrated service levels—reporting, EMR integration, and care-path support—to price tiers, so partners trade higher volumes for lower unit cost and stable diagnostic budgets; Myriad reported ~18% enterprise revenue growth in 2024.
- Discounts: 15–30% above 5,000 tests/yr
- Contract length: 3–5 years common
- Service add-ons: EMR, care-paths, reporting
- 2024 enterprise revenue growth: ~18%
Value-Based Contracting
Myriad is piloting value-based contracts that tie price to outcomes or total cost-of-care savings, e.g., GeneSight could be priced around its demonstrated 30% reduction in emergency visits for severe depression (2023 meta-analysis) and projected $1,200 annual per-patient savings in downstream costs.
These deals align Myriad revenue with patient clinical gains and payer cost-efficiency, shifting risk to shared-savings or outcomes-linked rebates used in commercial and Medicare Advantage pilots in 2024–25.
- Link price to outcomes (reduced ER visits, readmissions)
- Target $1,000–$1,500 estimated annual savings per patient
- Use shared-savings or rebate triggers tied to validated endpoints
- Pilot with Medicare Advantage and large commercial payers 2024–25
Insurance-driven revenue, patient aid & discounts fueled 18% growth in 2024
Myriad prices via insurer reimbursement (~78% of 2024 revenue) plus patient estimates, assistance (45k patients, $18M aid in 2024), and tiered enterprise discounts (15–30% >5k tests/yr; 3–5y contracts); value-based pilots (Medicare Advantage, 2024–25) target $1,000–$1,500 annual savings per patient and supported 18% enterprise revenue growth in 2024.
| Metric | 2024 |
|---|---|
| Reimbursement % | ~78% |
| Tests processed | ~410,000 |
| Financial aid | 45,000 pts / $18M |
| Enterprise growth | ~18% |